BRAF and cancer: Although gain-of-function mutations of KRAS and BRAF have been identified as a contributor to SHP099 resistance (Mainardi et al., 2018), more than 77.4% (233/301) of all cancer cell lines with the wild types of both KRAS and BRAF were resistant to SHP099 treatment (Supplementary Figure S2A).